Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Targeting FGFR in Cancer Therapy: From Biological Mechanisms to Clinical Breakthroughs
Hot Spotlight
10 min read
Targeting FGFR in Cancer Therapy: From Biological Mechanisms to Clinical Breakthroughs
13 June 2025
This article reviews the biological mechanisms of FGFR dysregulation and clinical advances of FGFR inhibitors like erdafitinib in treating urothelial carcinoma and other malignancies with FGFR alterations.
Read →
ADC Revolution 2024: Breakthroughs in Targeted Cancer Therapy from Trop-2 to HER2
Hot Spotlight
17 min read
ADC Revolution 2024: Breakthroughs in Targeted Cancer Therapy from Trop-2 to HER2
12 June 2025
Explore major breakthroughs in antibody-drug conjugates (ADCs) in 2024, including key targets like Trop-2, HER2, EGFR, and c-Met. Learn about landmark drug approvals, late-stage clinical trials, and the future of precision cancer therapy.
Read →
B7-H3 (CD276) in Cancer Immunotherapy: Multifaceted Roles and Emerging Targeting Strategies
Hot Spotlight
14 min read
B7-H3 (CD276) in Cancer Immunotherapy: Multifaceted Roles and Emerging Targeting Strategies
11 June 2025
B7-H3 (CD276), a type I transmembrane glycoprotein, has garnered significant attention due to its overexpression in a wide range of human cancers.
Read →
Japan's IP Court Awards Record $150M in Landmark Pharma Patent Case: Toray vs. Generics
Hot Spotlight
5 min read
Japan's IP Court Awards Record $150M in Landmark Pharma Patent Case: Toray vs. Generics
10 June 2025
A landmark ruling by Japan’s IP High Court awarded record-breaking $150 million damages in the Nalfurafine (Remitch®) patent dispute. This case reshapes how pharmaceutical companies approach patent term extensions, generic entry strategies, and IP litigation risks.
Read →
May 2025 Patent Highlights: LP(a) inhibitor from CSPC is better?
May 2025 Patent Highlights: LP(a) inhibitor from CSPC is better?
10 June 2025
YS2302018 was discovered by CSPC and has been shown to effectively prevent the formation of Lp(a).
Read →
May 2025 Patent Highlights: Eli Lilly’s CRHR2 peptide agonists
May 2025 Patent Highlights: Eli Lilly’s CRHR2 peptide agonists
10 June 2025
Tirzepatide is not Lilly’s only contender in this field; its small-molecule agonist orforglipron also met primary endpoints in studies and is poised for regulatory submission and potential approval.
Read →
May 2025 Patent Highlights: Roche's tri-complex inhibitors
May 2025 Patent Highlights: Roche's tri-complex inhibitors
10 June 2025
F.Hoffmann-La Roche(Roche) disclosed two patent applications, WO2025093625A1 and WO2025104149A1, covering a series of novel macrocyclic KRAS G12C inhibitors.
Read →
May 2025 Patent Highlights: Eisbach’s ALC1 inhibitor
May 2025 Patent Highlights: Eisbach’s ALC1 inhibitor
10 June 2025
Eisbach Bio GmbH has disclosed two patent applications primarily focused on the use of ALC1 inhibitors in cancer treatment: WO2025088087A1 and WO2025088175A1.
Read →
May 2025 Patent Highlights: Monte Rosa's CDK2 molecular glue degraders
May 2025 Patent Highlights: Monte Rosa's CDK2 molecular glue degraders
10 June 2025
A recent Monte Rosa patent application (WO2025090727) covers eight compounds and reveals the possible structure of MRT-9643 (CDK2 MGD) (compound 6).
Read →
May 2025 Patent Highlights: Vertex’s NaV Inhibitors
May 2025 Patent Highlights: Vertex’s NaV Inhibitors
10 June 2025
Suzetrigine is the first non-opioid novel pain medication approved in over two decades for pain management; however, its efficacy appears to be limited.
Read →
Hiro-LS Evolves into Patsnap Eureka LS - The Era of Biopharma AI Agents Begins Now
Feature Updates
3 min read
Hiro-LS Evolves into Patsnap Eureka LS - The Era of Biopharma AI Agents Begins Now
9 June 2025
Patsnap Eureka LS marks our transformation from a large language model into an intelligent AI Agent platform, purpose-built for the biopharmaceutical industry.
Read →
Patent Drafting Pitfalls: Alnylam's Custom Definition Sinks COVID-19 Vaccine Lawsuit
Hot Spotlight
5 min read
Patent Drafting Pitfalls: Alnylam's Custom Definition Sinks COVID-19 Vaccine Lawsuit
6 June 2025
On June 4, 2025, the CAFC issued a precedential decision in a patent infringement case involving mRNA-based COVID-19 vaccines, addressing whether the patentee’s “custom” definition of a term constituted infringement.
Read →